Physician profile
Shanah Gavia
NPI 1457895179
$5,139.08
in general payments reported to CMS, 2019-2025
25 companies · $1,133 in 2025
The $1,133 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,382 · 2022: $684 · 2023: $1,226 · 2024: $715 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,958 · Education: $99.99 · Travel and Lodging: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,958.13 |
| Education | $99.99 |
| Travel and Lodging | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,812.61 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $705.29 | 2021-2024 | Ilumya |
| Journey Medical Corporation | $573.07 | 2023-2025 | Emrosi |
| Lilly USA, LLC | $280.25 | 2021-2023 | Olumiant, Taltz |
| Genzyme Corporation | $254.27 | 2021-2024 | |
| Galderma Laboratories, L.P. | $254.24 | 2021-2024 | |
| Allergan, INC. | $185.35 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $145.82 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $144.27 | 2021-2022 | |
| Janssen Biotech, INC. | $133.33 | 2021 | |
| Sanofi-Aventis U.S. LLC | $78.47 | 2021 | |
| Genentech USA, INC. | $72.73 | 2022 | |
| Incyte Corporation | $68.67 | 2022-2023 | Opzelura |
| Janssen Scientific Affairs, LLC | $60.00 | 2022 | |
| Ucb, INC. | $51.69 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $48.43 | 2021 | |
| Vyne Pharmaceuticals INC. | $47.61 | 2021 | |
| Merz North America, INC. | $45.92 | 2022-2023 | Xeomin |
| Amgen INC. | $33.78 | 2023 | Otezla |
| Novartis Pharmaceuticals Corporation | $30.17 | 2025 | |
| Revance Therapeutics, INC. | $25.69 | 2024 | Daxxify |
| Lnhc, INC | $24.90 | 2025 | Zelsuvmi |
| Solta Medical, A Division of Bausch Health US, LLC | $22.50 | 2022 | |
| Leo Pharma INC. | $20.02 | 2021 | |
| Pfizer INC. | $20.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shanah Gavia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.